2Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease [ J ]. Clin Infect Dis, 2000, 30(4) : 710 -718.
3Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group[J]. N Engl J Med, 1999, 340(10) : 764 -771.
4Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations [ J]. Clin Ther, 2003, 25 (5) : 1295 - 1320.
5Comely OA, Maertens J, Bresnik M, et al. Liposomal amphoteriein B as initial therapy for invasive mold infection:A randomized trial comparing a high-loading dose regimen with stand ard dosing (AmBiload trial) [J]. Clin Infect Dis, 2007, 44(10) : 1289 - 1297.
6De Socio GV, Fiorio M, Stagni G. AmBisome administration for Candida albicans shunt infections [ J ]. Antimicrob Chemother, 2003, 52(6) : 1048 -1049.
8Besson I, Ingrand P, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med, 1995,333:555 -560.?A
9Jenkins SA, Shields R, Davies M, et al. A multicentre randomised trail comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut, 1997,41:526-533.?A
10Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology,2002,123:1013-1019.?A
